There is no evidence that shielding benefited vulnerable people during the Covid pandemic, according to a study.
Swansea University compared 117,000 people shielding in Wales with the rest of the population of three million.
The study found deaths and healthcare usage were higher among shielding people than the general population.
The Welsh government said shielding was introduced on medical and scientific advice and it will continue to review evidence from the pandemic.
The study also found the Covid rate was higher among those shielding – 5.9% compared to 5.7%.
The researchers said the data raised questions about whether the policy worked.
Although rare, a statistically significant association between BNT162b2 vaccination and myo/pericarditis and AKI was observed. While the association between BNT162b2 and myo/pericarditis has been confirmed internationally, further research is required to understand the association of AKI. BNT162b2 was not found to be associated with most of the AESIs investigated, providing reassurances around the safety of the vaccine.
Dr. John Campbell is an internet sensation, giving facts & data to help us navigate healthcare in the present day. The interview covers John’s development, work, rise to fame & what he would do to help get healthcare back in shape.
Four outcomes met the threshold for a statistical signal following BNT162b2 vaccination including pulmonary embolism (PE; RR = 1.54), acute myocardial infarction (AMI; RR = 1.42), disseminated intravascular coagulation (DIC; RR = 1.91), and immune thrombocytopenia (ITP; RR = 1.44). After further evaluation, only the RR for PE still met the statistical threshold for a signal; however, the RRs for AMI, DIC, and ITP no longer did. No statistical signals were identified following vaccination with either the mRNA-1273 or Ad26 COV2.S vaccines.
This early warning system is the first to identify temporal associations for PE, AMI, DIC, and ITP following BNT162b2 vaccination in the elderly. Because an early warning system does not prove that the vaccines cause these outcomes, more robust epidemiologic studies with adjustment for confounding, including age and nursing home residency, are underway to further evaluate these signals. FDA strongly believes the potential benefits of COVID-19 vaccination outweigh the potential risks of COVID-19 infection.
Nearly half of Americans believe Covid vaccines have probably caused a significant number of unexplained deaths, according to a Rasmussen Reports survey last week. In December, Rasmussen reported that a near equal proportion worry that Covid vaccines may have major side effects (57%) as believe they are effective (56%).
People can hold both views at the same time. But the self-professed expert class and many who call themselves journalists dismiss anyone who questions their Covid vaccine orthodoxy as an “anti-vaxxer”—a label as sneering as “climate denier.”
But surveys show that most Americans, including those who didn’t get Covid shots, don’t distrust vaccines in general. Public views on Covid vaccines are more complicated because they are new and haven’t been thoroughly studied. The experts are responsible for vaccine skepticism because they aren’t honest about the potential risks.
The purpose of this study is to determine the ECG parameter change and the efficacy of ECG screening for cardiac adverse effect after the second dose of BNT162b2 vaccine in young population. In December 2021, in cooperation with the school vaccination system of Taipei City government, we performed a ECG screening study during the second dose of BNT162b2 vaccines. Serial comparisons of ECGs and questionnaire survey were performed before and after vaccine in four male-predominant senior high schools. Among 7934 eligible students, 4928 (62.1%) were included in the study. The male/female ratio was 4576/352. In total, 763 students (17.1%) had at least one cardiac symptom after the second vaccine dose, mostly chest pain and palpitations. The depolarization and repolarization parameters (QRS duration and QT interval) decreased significantly after the vaccine with increasing heart rate. Abnormal ECGs were obtained in 51 (1.0%) of the students, of which 1 was diagnosed with mild myocarditis and another 4 were judged to have significant arrhythmia. None of the patients needed to be admitted to hospital and all of these symptoms improved spontaneously. Using these five students as a positive outcome, the sensitivity and specificity of this screening method were 100% and 99.1%, respectively. Conclusion: Cardiac symptoms are common after the second dose of BNT162b2 vaccine, but the incidences of significant arrhythmias and myocarditis are only 0.1%. The serial ECG screening method has high sensitivity and specificity for significant cardiac adverse effect but cost effect needs further discussed. What is Known: • The incidence of cardiac adverse effects was reported to be as high as 1.5 per 10 000 persons after the second dose BNT162b2 COVID-19 vaccine in the young male population based on the reporting system. What is New: • Through this mass ECG screening study after the second dose of BNT162b2 vaccine we found: (1) The depolarization and repolarization parameters (QRS duration and QT interval) decreased significantly after the vaccine with increasing heart rate; (2) the incidence of post-vaccine myocarditis and significant arrhythmia are 0.02% and 0.08%; (3) The serial ECG screening method has high sensitivity and specificity for significant cardiac adverse effect.
Extensive antibody profiling and T-cell responses in the individuals who developed postvaccine myocarditis were essentially indistinguishable from those of vaccinated control subjects, despite a modest increase in cytokine production. A notable finding was that markedly elevated levels of full-length spike protein (33.9±22.4 pg/mL), unbound by antibodies, were detected in the plasma of individuals with postvaccine myocarditis, whereas no free spike was detected in asymptomatic vaccinated control subjects (unpaired t test; P<0.0001).
Immunoprofiling of vaccinated adolescents and young adults revealed that the mRNA vaccine–induced immune responses did not differ between individuals who developed myocarditis and individuals who did not. However, free spike antigen was detected in the blood of adolescents and young adults who developed post-mRNA vaccine myocarditis, advancing insight into its potential underlying cause.
Commentary from Wall Street Journal Article: ‘Experts’ Are Fueling Distrust in Vaccines
An article in the American Heart Association’s journal Circulation last week found a link between myocarditis in teens and higher circulating levels of vaccine spike proteins in the blood. The authors found no correlation with vaccine antibody or T-cell responses, suspected by many as the cause of myocarditis.
∗ Across 31 systematically identified national seroprevalence studies in the pre-vaccination era, the median infection fatality rate of COVID-19 was estimated to be 0.034% for people aged 0–59 years people and 0.095% for those aged 0–69 years.
∗ The median IFR was 0.0003% at 0–19 years, 0.002% at 20–29 years, 0.011% at 30–39 years, 0.035% at 40–49 years, 0.123% at 50–59 years, and 0.506% at 60–69 years.
∗ At a global level, pre-vaccination IFR may have been as low as 0.03% and 0.07% for 0–59 and 0–69 year old people, respectively.
∗ These IFR estimates in non-elderly populations are lower than previous calculations had suggested.
Norway, Sweden and Iceland had the lowest relative cumulative excess mortality.
- Between the week ending 3 January 2020 (week 1 2020) and the week ending 1 July 2022 (week 26 2022), the UK’s relative cumulative excess mortality was 3.1% above the average of 2015 to 2019; this was over a third less than the cumulative excess mortality in the week ending 18 June 2021 (week 24 2021; the period of the previous article), at 5.8%.
- The UK had the 16th highest relative cumulative excess mortality of the 33 countries analysed (UK, its constituent countries, and 28 European countries), and 15th highest of 28 countries when constituent countries are removed.
- The majority of European countries analysed (25 of 33) experienced above average relative cumulative excess mortality for the whole period, with eight countries showing relative cumulative mortality below average.
- Bulgaria had the highest relative cumulative excess mortality at 18.2% above average, followed by Poland (13.3% above average) and Romania (12.2% above average); Norway had the lowest with 4.1% below average, followed by Sweden (4.0% below average) and Iceland (3.9% below average).
- The majority of European countries (22 of 33) had higher relative cumulative excess mortality in those aged 65 years and over compared with those aged under 65 years.
- The UK had the fifth highest relative cumulative excess mortality rate in those aged under 65 years (8.3% above average); in those aged 65 years and over in the UK, the cumulative excess mortality rate was the 19th highest (2.2% above average).
- Overall, 19 of the 33 European countries had a decrease in their relative cumulative excess mortality rates since the last release (week ending 18 June 2021), including the UK and constituent countries; the largest decrease was in Czechia (5.4 percentage points lower), whereas the largest increase was in Cyprus (5.4 percentage points higher).
SARS-CoV-2 vaccination was associated with higher risk of myocarditis death, not only in young adults but also in all age groups including the elderly. Considering healthy vaccinee effect, the risk may be 4 times or higher than the apparent risk of myocarditis death. Underreporting should also be considered. Based on this study, risk of myocarditis following SARS-CoV-2 vaccination may be more serious than that reported previously.
Across 31 systematically identified national seroprevalence studies in the pre-vaccination era, the median infection fatality rate of COVID-19 was estimated to be 0.035% for people aged 0-59 years people and 0.095% for those aged 0-69 years.
The median IFR was
* 0.0003% at 0-19 years
* 0.003% at 20-29 years
* 0.011% at 30-39 years
* 0.035% at 40-49 years
* 0.129% at 50-59 years
* and 0.501% at 60-69 years.
At a global level, pre-vaccination IFR may have been as low as 0.03% and 0.07% for 0-59 and 0-69 year old people, respectively.
These IFR estimates in non-elderly populations are lower than previous calculations had suggested.
From April 2020 through at least the end of 2021, Americans died from non-Covid causes at an average annual rate 97,000 in excess of previous trends. Hypertension and heart disease deaths combined were elevated 32,000. Diabetes or obesity, drug-induced causes, and alcohol-induced causes were each elevated 12,000 to 15,000 above previous (upward) trends. Drug deaths especially followed an alarming trend, only to significantly exceed it during the pandemic to reach 108,000 for calendar year 2021. Homicide and motor-vehicle fatalities combined were elevated almost 10,000. Various other causes combined to add 18,000. While Covid deaths overwhelmingly afflict senior citizens, absolute numbers of non-Covid excess deaths are similar for each of the 18-44, 45-64, and over-65 age groups, with essentially no aggregate excess deaths of children. Mortality from all causes during the pandemic was elevated 26 percent for working-age adults (18-64), as compared to 18 percent for the elderly. Other data on drug addictions, non-fatal shootings, weight gain, and cancer screenings point to a historic, yet largely unacknowledged, health emergency.
The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease.
Dr Peter McCullough MD is America’s leading cardiologist and one of its most articulate and fearless sceptics about the official Covid narrative. He talks to James about needless ‘Covid’ deaths, the importance of early treatment, the deliberate suppression of effective cures and his concerns about vaccine side effects, including the increased incidence of myocarditis especially among young men.
There are signs that the latest wave of Covid infections may have peaked in children and younger adults, according to scientists tracking the outbreak.
But rates in those older groups most vulnerable to severe disease are continuing to increase in England.
Millions of Britons could need Covid boosters every six months for the foreseeable future, a health boss hinted today.
Dr Jenny Harries, chief executive of the UK Health Security Agency (UKHSA), suggested the most vulnerable ‘relevant groups’ in society will still need regular top-up jabs.
The boy – aged between 11 and 12 – fell ill just after 1pm today at lunchtime
Police and ambulance rushed to Shoeburyness High School to try and save him
Tonight Essex Police confirmed it was investigating and death was ‘unexplained’
‘Former BlackRock Portfolio Manager, Investor Edward Dowd, Explains Bombshell ‘Fraud’ Charge re Pfizer Hiding Deaths Data; Many Media Outlets are ‘Accomplices to Murder’ DO NOT MISS. Historic.’
Edward Dowd Interview portion on Steve Bannons War Room Ep #1602
Two weeks ago the Centers for Disease Control and Prevention (CDC) published data about the effectiveness of boosters against COVID-19
The CDC failed to publish a tranche of their data, however – omitting the impact on those aged 18-49, who are least likely to benefit from boosters
The CDC are also being criticized for failing to publish their information about child hospitalization rates and comorbidities
A spokeswoman for the CDC said they were concerned that the data would be misinterpreted, pointing out that it was incomplete and not verified
Critics said that it was always better to publish the information rather than withhold, and allow scientists to analyze and explain what they could
Question What is the risk of myocarditis after mRNA-based COVID-19 vaccination in the US?
Findings In this descriptive study of 1626 cases of myocarditis in a national passive reporting system, the crude reporting rates within 7 days after vaccination exceeded the expected rates across multiple age and sex strata. The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively).
Meaning Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men.